Vaccine Protection Through Placenta and Breastfeeding: The Unmet Topic in COVID-19 Pandemic DOI Creative Commons
Ariane Laguila Altoé,

Anna Paula Marques Mambriz,

Daniela Máira Cardozo

и другие.

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Июнь 3, 2022

The coronavirus disease 2019 (COVID-19) pandemic has turned pregnant women’s healthcare into a worldwide public health challenge. Although initial data did not demonstrate pregnancy as more susceptible period to severe outcomes of acute respiratory syndrome-related 2 (SARS-CoV-2) infection, there are an increasing number reports showing that only women might be at significantly higher risk than non-pregnant by COVID-19 but also the fetus. These findings may related adaptive changes occur during pregnancy, such reduction in residual capacity, decrease viral immune responses, and increased for thromboembolic events. Additionally, despite SARS-CoV-2 vertical transmission evidence being uncommon, maternal illness severity reflect serious perinatal neonatal outcomes. Thus, protecting maternal–fetal dyad against is critical. Even though initially were excluded from vaccine trials, several studies have provided safety efficacy overall platforms. Vaccination becomes priority can generate benefits both mother newborn: neutralizing antibodies transmitted through placenta breastfeeding. Moreover, regarding passive immunization, human milk contains other bioactive molecules cells able modulate newborn’s response, which amplified after vaccine. Nonetheless, many issues remain elucidated, considering magnitude protective immunity transferred, duration induced immunity, optimal interval immunization. In this review, we assessed these unmet topics supported literature vaccine’s immunogenicity, heterogeneity, unique antiviral features.

Язык: Английский

SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland DOI Creative Commons
Sarah J. Stock, Jade Carruthers, Clara Calvert

и другие.

Nature Medicine, Год журнала: 2022, Номер 28(3), С. 504 - 512

Опубликована: Янв. 13, 2022

Abstract Population-level data on COVID-19 vaccine uptake in pregnancy and SARS-CoV-2 infection outcomes are lacking. We describe pregnant women Scotland, using whole-population from a national, prospective cohort. Between the start of program 8 December 2020 31 October 2021, 25,917 vaccinations were given to 18,457 women. Vaccine coverage was substantially lower than general female population 18−44 years; 32.3% giving birth 2021 had two doses compared 77.4% all The extended perinatal mortality rate for who gave within 28 d diagnosis 22.6 per 1,000 births (95% CI 12.9−38.5; pandemic background 5.6 births; 452 out 80,456; 95% 5.1−6.2). Overall, (3,833 4,950; 76.2−78.6) infections, 90.9% (748 823; 88.7−92.7) associated with hospital admission 98% (102 104; 92.5−99.7) critical care admission, as well baby deaths, occurred unvaccinated at time diagnosis. Addressing low rates is imperative protect health babies ongoing pandemic.

Язык: Английский

Процитировано

263
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy DOI Creative Commons
Xin Bai,

Qijing Chen,

Fengqiao Li

и другие.

Nature Communications, Год журнала: 2024, Номер 15(1)

Опубликована: Авг. 9, 2024

Lipid nanoparticle-assisted mRNA inhalation therapy necessitates addressing challenges such as resistance to shear force damage, mucus penetration, cellular internalization, rapid lysosomal escape, and target protein expression. Here, we introduce the innovative "LOOP" platform with a four-step workflow develop inhaled lipid nanoparticles specifically for pulmonary delivery. iLNP-HP08LOOP featuring high helper ratio, acidic dialysis buffer, excipient-assisted nebulization demonstrates exceptional stability enhanced expression in lungs. By incorporating encoding IL-11 single chain fragment variable (scFv), scFv@iLNP-HP08LOOP effectively delivers secretes scFv lungs of male mice, significantly inhibiting fibrosis. This formulation surpasses both intravenously injected fibroblast activation extracellular matrix deposition. The HP08LOOP system is also compatible commercially available ALC0315 LNPs. Thus, method presents powerful developing nanotherapeutics potential treating various respiratory diseases, including idiopathic Inhaled face several when delivered authors show "LOOP"-optimized could withstand damage generated during process be used mRNA-mediated antibody

Язык: Английский

Процитировано

19
Vaccination and immunotherapies in neuroimmunological diseases DOI Open Access

Alexander Winkelmann,

Micha Loebermann, Michael Barnett

и другие.

Nature Reviews Neurology, Год журнала: 2022, Номер 18(5), С. 289 - 306

Опубликована: Апрель 6, 2022

Язык: Английский

Процитировано

48
Influence of the COVID-19 pandemic and social media on the behaviour of pregnant and lactating women towards vaccination: a scoping review DOI Creative Commons
Larissa De Brabandere, Greet Hendrickx, Karolien Poels

и другие.

BMJ Open, Год журнала: 2023, Номер 13(2), С. e066367 - e066367

Опубликована: Фев. 1, 2023

Background Pregnant women, foetuses and infants are at risk of infectious disease-related complications. Maternal vaccination is a strategy developed to better protect pregnant women their offspring against morbidity mortality. Vaccines influenza, pertussis recently also COVID-19 widely recommended for women. Yet, there still significant amount hesitation towards maternal policies. Furthermore, contradictory messages circulating social media impact vaccine confidence. Objectives This scoping review aims reveal how impacted confidence in lactating Additionally, this studied the role plays creating opinions these target groups. Eligibility criteria Articles published between 23 November 2018 18 July 2022 that linked objectives were included. Reviews, articles not focusing on group, abstracts, describing outcomes infection/COVID-19 excluded. Sources evidence The PubMed database was searched select articles. Search terms used pregnancy, lactation, vaccination, hesitancy, media. Charting methods Included abstracted synthesised by one reviewer. Verification done second Disagreements addressed through discussion reviewers other researchers. Results generally less likely accept compared with non-pregnant non-nursing main reason refuse safety concerns. A positive link detected willingness acceptance vaccines during pregnancy. internet identified as important information sources vaccination. Discussion conclusion Vaccine hesitancy remains an issue, expressing need effective interventions increase coverage. uptake unclear.

Язык: Английский

Процитировано

24
Evidence-Based Policies in Public Health to Address COVID-19 Vaccine Hesitancy DOI
Francesco Chirico, Jaime A. Teixeira da Silva

Future Virology, Год журнала: 2023, Номер 18(4), С. 261 - 273

Опубликована: Март 1, 2023

A fundamental basis for effective health-related policymaking of any democratic nation should be open and transparent communication between a government its citizens, including scientists healthcare professionals, to foster climate trust, especially during the ongoing COVID-19 mass vaccination campaign. Since misinformation is leading cause vaccine hesitancy, data sharing through an evidence-based approach may render health strategies developed by policymakers with public more effective, allowing claims that are not backed scientific evidence tackled. In this narrative review, we debate possible causes hesitancy links epidemic. We also put forward plausible solutions as recommended in literature.

Язык: Английский

Процитировано

24
COVID-19 Vaccines over Three Years after the Outbreak of the COVID-19 Epidemic DOI Creative Commons
Aleksandra Anna Zasada, Aniela Darlińska,

Aldona Wiatrzyk

и другие.

Viruses, Год журнала: 2023, Номер 15(9), С. 1786 - 1786

Опубликована: Авг. 23, 2023

The outbreak of COVID-19 started in December 2019 and spread rapidly all over the world. It became clear that development an effective vaccine was only way to stop pandemic. first time history infectious diseases process a new conducted on such large scale accelerated so rapidly. At end 2020, vaccines were approved for marketing. March 2023, three years after pandemic, 199 pre-clinical 183 clinical development. candidate phase are based following platforms: protein subunit, DNA, RNA, non-replication viral vector, replicating inactivated virus, virus-like particles, live attenuated vector combined with antigen-presenting cell, bacterial antigen-spore expression vector. Some platforms have been human application. This review presents currently available world, procedures assurance quality safety vaccines, vaccinated population, as well future perspectives drug therapy non-infectious diseases.

Язык: Английский

Процитировано

23
Systematic review and meta-analysis of neonatal outcomes of COVID-19 vaccination in pregnancy DOI Creative Commons
Dingning Zhang, Ting‐Ting Huang, Zhihui Chen

и другие.

Pediatric Research, Год журнала: 2023, Номер 94(1), С. 34 - 42

Опубликована: Янв. 3, 2023

Abstract Background The safety of coronavirus disease 2019 (COVID-19) vaccines during pregnancy is a particular concern. Here, we addressed the neonatal outcomes after maternal vaccination COVID-19 pregnancy. Methods We systematically searched PubMed, EMBASE, and WHO Database for studies on from inception to 3 July 2022. Main were related preterm, small gestation (SGA), NICU admission, low Apgar score at 5 min (<7), additional such as <34 weeks, birth weight some morbidity all also analyzed. Results A total 15 included. found that was reduction rates Preterm, SGA, Low (<7). In addition, there no evidence higher risk adverse pregnancy, including preterm with weight, very congenital anomalies, so on. Conclusions in pregnant women does not raise significant effects protective effect outcomes. Impact Present study has present could encourage be vaccinated against COVID-19.

Язык: Английский

Процитировано

21
Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis DOI Creative Commons

Wanqian Xu,

Weigang Ren,

Tongxin Wu

и другие.

Vaccines, Год журнала: 2023, Номер 11(6), С. 1118 - 1118

Опубликована: Июнь 19, 2023

With the mass vaccination program for COVID-19 mRNA vaccines, there has been sufficient real-world study (RWS) on topic to summarize their safety in total population and immunocompromised (IC) patients who were excluded from phase 3 clinical trials. We conducted a systematic review meta-analysis evaluate of with 5,132,799 subjects 122 articles. In case vaccinated first, second, third doses, pooled incidence any adverse events (AEs) was 62.20%, 70.39%, 58.60%; that local AEs 52.03%, 47.99%, 65.00%; systemic 29.07%, 47.86%, 32.71%. Among patients, odds ratio AEs, slightly lower than or similar those healthy controls at 0.60 (95% CI: 0.33–1.11), 0.19 0.10–0.37), 0.36 0.25–0.54), incidences 51.95%, 38.82%, 31.00%, respectively. The spectrum associated vaccines broad, but most transient, self-limiting, mild moderate. Moreover, younger adults, women, people prior SARS-CoV-2 infection more likely experience AEs.

Язык: Английский

Процитировано

18
Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe DOI Open Access
Arkadiusz Dziedzic, Abanoub Riad, Sameh Attia

и другие.

Journal of Clinical Medicine, Год журнала: 2021, Номер 10(22), С. 5338 - 5338

Опубликована: Ноя. 16, 2021

Optimization of COVID-19 vaccination rate among healthcare personnel is utmost priority to secure provision uninterrupted care and protect the most vulnerable patients. This study, as part global CoVaST project, aimed assess occurrence short-term adverse events (SRAEs) two administered vaccines, mRNA-based (Pfizer-BioNTech Moderna) viral vector-based (AstraZeneca) in sector workers (HWs).

Язык: Английский

Процитировано

37
Challenges of vaccination and herd immunity in COVID‐19 and management strategies DOI
Jun She, Dongni Hou, Cuicui Chen

и другие.

The Clinical Respiratory Journal, Год журнала: 2022, Номер 16(11), С. 708 - 716

Опубликована: Сен. 29, 2022

Coronavirus disease 2019 (COVID-19), the highly contagious viral caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide with millions of cases and more than 5 million deaths to date. SARS-CoV-2 serious damage all over world many countries experiencing third or fourth wave outbreaks, mainly due emergence mutant variants. Those who unvaccinated remain most vulnerable COVID-19 its vaccination, along prevention strategies, is a critical measure defense against disease. vaccination can reduce virus help protect susceptible population. Although herd immunity might not be realized solely vaccines have been proved effective in reducing risk disease, hospitalization, even death. It recommended that people get vaccinated as soon they are eligible. This review summarizes recent variants brought challenges for discusses promising management strategies.

Язык: Английский

Процитировано

26